Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Bought by NorthRock Partners LLC

NorthRock Partners LLC grew its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 14.4% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 3,365 shares of the medical research company’s stock after purchasing an additional 423 shares during the period. NorthRock Partners LLC’s holdings in Thermo Fisher Scientific were worth $2,081,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. United Community Bank grew its position in Thermo Fisher Scientific by 14.0% in the 1st quarter. United Community Bank now owns 203 shares of the medical research company’s stock valued at $118,000 after buying an additional 25 shares in the last quarter. BI Asset Management Fondsmaeglerselskab A S raised its holdings in Thermo Fisher Scientific by 24.2% during the first quarter. BI Asset Management Fondsmaeglerselskab A S now owns 11,480 shares of the medical research company’s stock worth $6,672,000 after purchasing an additional 2,234 shares in the last quarter. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors bought a new position in Thermo Fisher Scientific during the 1st quarter valued at $251,000. Callan Capital LLC acquired a new position in shares of Thermo Fisher Scientific during the 1st quarter valued at $287,000. Finally, TFB Advisors LLC bought a new position in Thermo Fisher Scientific during the first quarter valued at about $245,000. Institutional investors own 89.23% of the company’s stock.

Thermo Fisher Scientific Stock Up 0.5 %

NYSE:TMO traded up $2.79 during trading hours on Tuesday, reaching $558.26. The company’s stock had a trading volume of 115,051 shares, compared to its average volume of 1,457,122. Thermo Fisher Scientific Inc. has a one year low of $437.26 and a one year high of $627.88. The business’s 50-day moving average is $598.39 and its 200-day moving average is $583.86. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.63 and a quick ratio of 1.26. The company has a market cap of $213.26 billion, a price-to-earnings ratio of 34.83, a price-to-earnings-growth ratio of 3.69 and a beta of 0.79.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings data on Wednesday, October 23rd. The medical research company reported $5.28 earnings per share for the quarter, beating analysts’ consensus estimates of $5.25 by $0.03. Thermo Fisher Scientific had a return on equity of 17.49% and a net margin of 14.48%. The business had revenue of $10.60 billion for the quarter, compared to the consensus estimate of $10.63 billion. During the same period last year, the business earned $5.69 EPS. The firm’s revenue was up .2% compared to the same quarter last year. Equities research analysts predict that Thermo Fisher Scientific Inc. will post 21.68 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on TMO shares. Bernstein Bank upped their price target on shares of Thermo Fisher Scientific from $565.00 to $625.00 and gave the company a “market perform” rating in a report on Tuesday, October 22nd. Bank of America lifted their price target on shares of Thermo Fisher Scientific from $600.00 to $675.00 and gave the stock a “buy” rating in a research report on Monday, September 16th. Barclays reduced their price objective on Thermo Fisher Scientific from $620.00 to $610.00 and set an “equal weight” rating for the company in a research note on Wednesday, October 23rd. Stifel Nicolaus dropped their price target on Thermo Fisher Scientific from $680.00 to $665.00 and set a “buy” rating on the stock in a research note on Thursday, October 24th. Finally, UBS Group upgraded shares of Thermo Fisher Scientific to a “strong-buy” rating in a report on Monday, September 16th. Four equities research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $649.33.

Insider Buying and Selling

In other news, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction dated Monday, October 28th. The stock was sold at an average price of $554.29, for a total value of $5,542,900.00. Following the transaction, the chief executive officer now directly owns 121,192 shares in the company, valued at approximately $67,175,513.68. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other news, CEO Marc N. Casper sold 5,850 shares of Thermo Fisher Scientific stock in a transaction that occurred on Friday, November 1st. The stock was sold at an average price of $557.89, for a total transaction of $3,263,656.50. Following the sale, the chief executive officer now owns 121,192 shares of the company’s stock, valued at approximately $67,611,804.88. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction on Monday, October 28th. The stock was sold at an average price of $554.29, for a total value of $5,542,900.00. Following the completion of the transaction, the chief executive officer now directly owns 121,192 shares of the company’s stock, valued at approximately $67,175,513.68. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 18,150 shares of company stock worth $10,094,925 in the last quarter. 0.34% of the stock is currently owned by company insiders.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.